Bank of New York Mellon Corp Reduces Position in AbbVie Inc. $ABBV

Bank of New York Mellon Corp trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 1.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,301,919 shares of the company’s stock after selling 204,578 shares during the period. Bank of New York Mellon Corp’s holdings in AbbVie were worth $2,848,386,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Evolution Wealth Management Inc. purchased a new position in AbbVie in the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the second quarter valued at approximately $36,000. Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $39,000. Finally, Bear Mountain Capital Inc. lifted its position in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ABBV. Morgan Stanley upped their target price on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. UBS Group restated a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $247.84.

AbbVie Price Performance

Shares of ABBV opened at $223.92 on Wednesday. The firm has a 50-day simple moving average of $225.14 and a two-hundred day simple moving average of $218.00. The stock has a market cap of $395.75 billion, a PE ratio of 169.64, a P/E/G ratio of 0.91 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 524.24%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck billion‑dollar licensing deals with Novartis for oncology and Alzheimer’s programs, which expand near‑ and long‑term revenue optionality and signal external validation of AbbVie’s R&D. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Berenberg raised its price target (to $275) and remains bullish on Skyrizi and Rinvoq momentum, a supportive analyst view that can boost investor sentiment. Berenberg Grows More Confident in AbbVie on Skyrizi and Rinvoq Momentum
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector delivering risankizumab, which could improve dosing convenience and broaden uptake for indications served by Skyrizi. This is a pipeline/utility win. AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion
• Positive Sentiment: Small institutional buying reported (Belpointe Asset Management increased its stake), a modest signal of shareholder confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Neutral Sentiment: Options and retail interest are elevated (coverage from Zacks on options flow and trending status); this can increase volatility but isn’t a fundamental catalyst by itself. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Corporate social impact news (AbbVie Foundation accelerator) and dividend‑king listings support the long‑term income story but are not immediate earnings drivers. The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program named several AbbVie drugs for its next negotiation cycle, including Part B products — a direct pricing risk that could pressure future revenues if negotiated prices are reduced. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: A competitor (Corcept) reported robust Phase III efficacy for an ovarian cancer drug, which could threaten market share in oncology areas where AbbVie competes. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
• Negative Sentiment: Citigroup trimmed its price target to $230 and assigned a neutral rating, a modest analyst headwind that may cap upside near‑term. Citigroup Lowers Price Target on AbbVie

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.